Metabolic Blend: NAD+ / MOTS-c / 5-Amino-1MQ (100mg / 10mg / 10mg)

NAD+ — Coenzyme Substrate Replenishment Across Four Critical Enzymatic Systems

NAD+ functions as the central metabolic currency connecting cellular energy production, genome maintenance, epigenetic regulation, and stress response:

Mitochondrial Energy Production

• In its reduced form NADH, NAD+ carries high-energy electrons from the citric acid cycle to Complex I of the electron transport chain — the first step of oxidative phosphorylation that generates the proton gradient driving ATP synthase​
• Complex I oxidizes NADH back to NAD+, regenerating the coenzyme for further metabolic reactions; when NAD+ is depleted, this cycle stalls, impairing cellular ATP production at its most fundamental level
• The NADH/NAD+ ratio is a master sensor of cellular energy status — a high ratio signals energy excess; a low ratio signals energetic stress and activates catabolic programs​

Sirtuin Activation — Epigenetic Regulation and Mitochondrial Biogenesis

• SIRT1–7 are NAD+-dependent protein deacetylases that require NAD+ as a co-substrate (consumed in each reaction, not catalytically recycled) — meaning sirtuin activity is directly limited by NAD+ availability
• SIRT1: Deacetylates and activates PGC-1α, the master regulator of mitochondrial biogenesis, fatty acid oxidation, and antioxidant defense; also activates FOXO transcription factors (stress resistance) and suppresses NF-κB (inflammation)
• SIRT3: Localizes to mitochondria; deacetylates and activates Complex I, isocitrate dehydrogenase, and MnSOD (mitochondrial antioxidant defense); directly links NAD+ availability to mitochondrial ROS control
• SIRT6: Deacetylates histones at DNA damage sites, activates DNA repair machinery, and regulates telomere maintenance

PARP1/2 — DNA Damage Sensing and Repair

• PARP1 consumes massive quantities of NAD+ (up to 100 molecules per activation event) in response to DNA strand breaks, adding poly-ADP-ribose chains to histones and other proteins to signal and coordinate DNA repair​
• Chronic DNA damage with aging triggers sustained PARP1 activation — creating an autocatalytic cycle where DNA damage depletes NAD+, impaired sirtuin activity reduces DNA repair, which generates more DNA damage, further depleting NAD+
• Restoring NAD+ breaks this cycle by providing substrate for both PARP (repair) and sirtuins (prevention)

CD38 — Calcium Signaling and Age-Related NAD+ Consumption

• CD38 is an ectoenzyme that increases substantially with age and inflammation; it hydrolyzes NAD+ to generate cyclic ADP-ribose (cADPR), a calcium-mobilizing messenger​
• Chronic CD38 upregulation by senescent cells and macrophages contributes meaningfully to age-related NAD+ decline — an important reason why simply supplementing NAD+ precursors may be insufficient in inflamed aging tissue
• Direct NAD+ (100 mg injectable) provides an acute surge in intracellular NAD+ availability that can overcome CD38-mediated consumption and directly replete sirtuin-accessible pools

NAD+ Biosynthesis Pathways — Why Precursor Form Matters

• NAD+ itself cannot efficiently enter most cells directly due to its charged phosphate groups and large molecular size​
• Oral/injectable precursors (NMN, NR) enter cells through dedicated transporters and are phosphorylated intracellularly to NAD+ — a more biologically efficient route for sustained tissue replenishment
• Injectable NAD+ produces rapid, large-amplitude plasma spikes but whether this translates to intracellular NAD+ elevation in target tissues (brain, muscle) or is primarily metabolized extracellularly remains debated among researchers​
• 5-Amino-1MQ (see below) addresses this limitation by preserving endogenous NAD+ production through NNMT inhibition — a complementary strategy that works from the biosynthetic side

MOTS-c — Mitochondrial-Nuclear Retrograde Signaling and Exercise Mimicry

MOTS-c operates through a mechanism unlike any other metabolic agent — it is a hormonal signal encoded by mitochondrial DNA that travels to the nucleus to reprogram gene expression in response to metabolic stress:

Folate-AICAR-AMPK Pathway — The Primary Metabolic Axis

• MOTS-c’s primary molecular mechanism begins in the folate cycle: MOTS-c inhibits key enzymes of the folate/one-carbon metabolic pathway, causing accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) — a purine synthesis intermediate
• Accumulated AICAR is a well-validated endogenous activator of AMP-activated protein kinase (AMPK) — the master cellular energy sensor that detects low ATP/AMP ratios and activates catabolic programs to restore energy balance
• AMPK activation by MOTS-c produces a coordinated metabolic shift: increased glucose uptake (GLUT4 translocation), enhanced fatty acid oxidation (ACC phosphorylation → reduced malonyl-CoA → increased CPT1 activity → mitochondrial fat import), upregulated mitochondrial biogenesis (via PGC-1α), and reduced anabolic energy consumption
• Critically, MOTS-c achieves this AMPK activation without energy depletion — it mimics the hormetic stress signal of exercise without the metabolic cost of exercise itself

Nuclear Translocation — Stress Adaptation Gene Expression

• Under metabolic stress or exercise, MOTS-c translocates from mitochondria to the cell nucleus where it directly modulates transcription of genes with Antioxidant Response Elements (AREs)
• Nuclear MOTS-c activates the Nrf2/ARE pathway — upregulating genes for glutathione synthesis, peroxiredoxins, thioredoxin reductase, and heme oxygenase-1 — a comprehensive antioxidant program
• MOTS-c also suppresses methionine metabolism — a key pathway in cellular aging; in rodents, methionine restriction extends lifespan by up to 45%​

NAD+ Elevation — The Convergence Point

• MOTS-c elevates intracellular NAD+ through AMPK-mediated upregulation of NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway)​
• SIRT1 mediates MOTS-c’s glycolytic actions downstream — meaning MOTS-c’s benefits are partly NAD+-dependent, and the two compounds in this blend are mutually reinforcing: NAD+ provides substrate; MOTS-c upregulates the enzymes that use it and produce more of it

Exercise Physiology — Endocrine Roles

• MOTS-c is released from skeletal muscle mitochondria during exercise and acts as an exercise-induced mitohormone — it signals throughout the body to coordinate metabolic adaptations to physical stress
• Exogenous MOTS-c in mice increased treadmill running duration in young mice by ~1.5–2x, middle-aged mice by a comparable magnitude, and old mice by 2-fold — with old mice on MOTS-c entering the highest speed stage (impossible without treatment)
• The mechanism involves both improved skeletal muscle insulin sensitivity (GLUT4/Akt pathway) and enhanced mitochondrial efficiency in responding to exercise-induced metabolic stress​

5-Amino-1MQ — NNMT Inhibition and Adipocyte Metabolic Reprogramming

5-Amino-1MQ targets Nicotinamide N-Methyltransferase (NNMT) — a cytosolic enzyme highly expressed in white adipose tissue that catalyzes the methylation of nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor:

The NNMT Problem — NAD+ Drain in White Adipose Tissue

• NNMT methylates nicotinamide to 1-methylnicotinamide (MNA), directing it away from the NAD+ salvage pathway (where NAMPT would normally convert it to NMN → NAD+)
• High NNMT activity in obese and aging white adipose tissue simultaneously: depletes the NAD+ precursor pool (less nicotinamide available for NAMPT), consumes SAM (reducing methylation capacity for epigenetic regulation), and shifts adipocytes toward a storage-dominant metabolic phenotype
• NNMT expression is elevated in obesity, type 2 diabetes, and aging — creating a self-reinforcing cycle where metabolic dysfunction upregulates NNMT, which further impairs NAD+-dependent metabolism​

5-Amino-1MQ Mechanism — Plugging the NAD+ Drain

• 5-Amino-1MQ is a methylquinolinium analog that competitively inhibits NNMT with high selectivity — it does not inhibit NAMPT, related methyltransferases, or NAD+ salvage pathway enzymes at relevant concentrations
• High membrane permeability (validated in parallel artificial membrane permeability [PAMPA] and Caco-2 cell assays) allows 5-Amino-1MQ to reach intracellular NNMT in adipocytes​
• NNMT inhibition redirects nicotinamide back into the NAMPT-mediated NAD+ salvage pathway → elevated intracellular NAD+ specifically in adipocytes

Downstream Metabolic Reprogramming in Adipocytes

• Elevated adipocyte NAD+ activates SIRT1 → upregulates PGC-1α → drives mitochondrial biogenesis and fatty acid oxidation programs within fat cells
• Enhanced AMPK signaling (partly NAD+/SIRT1-dependent) promotes catabolic pathways — the fat cell shifts from a storage-dominant to an energy-expenditure-dominant metabolic profile
• The most consistent subjective signal in user reports and mechanistically predicted sequence: energy and endurance improve first (mitochondrial biogenesis is upstream), followed by body composition changes (fat oxidation is downstream)​

The Complementarity with NAD+ and MOTS-c

• NAD+ injectable: floods the system with substrate — broad-spectrum coenzyme replenishment across all tissues​
• MOTS-c: reprograms the metabolic software — AMPK/PGC-1α activation, nuclear stress adaptation gene expression, improved insulin sensitivity in muscle
• 5-Amino-1MQ: stops the leak — prevents NNMT from siphoning the NAD+ precursor pool in the specific tissue (white adipose tissue) where NAD+ depletion has the greatest impact on body composition

Convergence Point: The NAD+/AMPK/SIRT1/PGC-1α Axis

All three components of this blend ultimately converge on the same downstream signaling network:

NAD+ / Precursor Research Evidence

NAD+ replenishment represents one of the most active areas of human aging research, with dozens of clinical trials of NAD+ precursors (NMN, NR) and a growing body of injectable NAD+ clinical experience:

• NR (Nicotinamide Riboside) — Phase 2 RCT (Elhassan et al., 2019): 12 healthy older men received NR supplementation; skeletal muscle NAD+ metabolome increased significantly with treatment; mitochondrial biogenesis markers improved​
• NR — Crossover RCT (Martens et al., 2018): 24 healthy middle-aged/older adults; 6-week NR supplementation at 500 mg/day significantly elevated whole blood NAD+ levels and was well tolerated with no serious adverse events​
• NMN — Multiple Phase 1/2 trials (2019–2023): At least 12 human clinical trials have evaluated NMN or NR; common findings include reliable NAD+ elevation in blood and muscle, modest improvements in insulin sensitivity in older adults with prediabetes, and improvements in gait speed and muscle performance in some populations
• NMN in older women (Yoshino et al., 2021): 10 weeks of NMN supplementation in postmenopausal women with prediabetes significantly improved muscle insulin signaling and muscle function compared to placebo​
• Injectable NAD+ vs. oral precursors: A 2024 pilot study comparing 500 mg IV NAD+ vs. 500 mg IV NR demonstrated that NR IV peaked higher and faster, with fewer side effects than NAD+ IV (which caused headaches, nausea in many subjects). Expert debate remains about whether IV NAD+ itself efficiently enters cells vs. being metabolized extracellularly — a genuine mechanistic uncertainty​
• Comprehensive PRISMA review (2020): Systematic review of all published human trials found consistent NAD+ elevation with supplementation and promising but preliminary signals for skin health, skeletal muscle function, and metabolic improvements — with a call for larger, longer trials to confirm clinical endpoints

MOTS-c Research Evidence

MOTS-c has a rapidly accumulating preclinical evidence base primarily from the USC Leonard Davis School of Gerontology group:

• Discovery paper (Lee et al., 2015, Cell Metabolism): First characterization of MOTS-c as a mitochondrial-encoded peptide; showed MOTS-c treatment prevented diet-induced obesity and age-dependent insulin resistance in mice; identified the Folate-AICAR-AMPK primary mechanism​
• Exercise mimetic (Lee et al., 2021, Nature Communications): MOTS-c treatment in young mice enhanced treadmill running performance; in middle-aged mice (12 months) produced a 2-fold increase in running duration and significantly improved running distance; in old mice (22 months) similarly doubled running capacity; late-life initiated MOTS-c treatment improved grip strength, gait, and physical performance in mice aged ~24 months; trended toward increased median lifespan (6.4%) and maximum lifespan (7.0%) with a hazard ratio of 0.654 (P=0.05)
• Plasma metabolomics (Lu et al., 2019): MOTS-c treatment in DIO mice reduced biomarkers of sphingolipid, monoacylglycerol, and dicarboxylate metabolism — all pathways upregulated in obesity and T2D — confirming broad metabolic normalization​
• Gestational diabetes (2021): MOTS-c significantly alleviated hyperglycemia, improved insulin sensitivity, and protected pancreatic β-cells from STZ-mediated injury in GDM mouse models​
• Exercise synergy (2021): MOTS-c combined with treadmill training produced additive/synergistic improvements in AMPK/PGC-1α/GLUT4 expression and insulin sensitivity beyond either intervention alone​
• Bone metabolism: MOTS-c promotes osteoblast proliferation and differentiation while inhibiting osteoclast production — providing a potential anti-osteoporosis mechanism as a secondary benefit​
• Human observational data: Endogenous circulating MOTS-c levels are significantly reduced in obese, type 2 diabetic, and elderly populations, and are positively correlated with exercise capacity and metabolic health markers
• Breast cancer survivor exercise study (2023): 12-week exercise program in breast cancer survivors produced increases in MOTS-c levels that correlated with improvements in body composition — the first human prospective exercise-MOTS-c correlation data​
• No human clinical trials using exogenous synthetic MOTS-c have been published as of early 2026

5-Amino-1MQ Research Evidence

5-Amino-1MQ has the thinnest human evidence base of the three compounds — all published research is preclinical:

• NNMT inhibitor selectivity characterization (Neelakantan et al., 2017): 5-Amino-1MQ demonstrated concentration-dependent NNMT inhibition in fully differentiated adipocytes with a clean selectivity profile — no inhibition of NAMPT or related methyltransferases at relevant concentrations​
• DIO obesity model (Neelakantan et al., 2018): Diet-induced obese mice treated with 5-Amino-1MQ showed: >30% decrease in adipocyte size, >40% decrease in adipocyte volume, ~35% decrease in epididymal white adipose tissue mass, ~5.1% total body weight loss, ~30% lower cholesterol — with no change in food intake, confirming a metabolism-driven mechanism rather than appetite suppression
• Insulin sensitivity improvement: 5-Amino-1MQ treatment improved glucose tolerance in the same DIO mouse model, consistent with restored adipocyte NAD+/SIRT1 signaling​
• No published human clinical trials by any route of administration exist for 5-Amino-1MQ as of early 2026
• Oral bioavailability in rats: 38.4% with a terminal half-life of 6.90 hours​
• The injectable route specifically has not been evaluated in any published preclinical study; SC injection data does not exist​

Regulatory Status

All three compounds occupy distinct and evolving regulatory positions:

• NAD+ (injectable): Not FDA-approved as a drug product for any therapeutic indication. Injectable NAD+ (typically formulated as lyophilized powder for reconstitution) is widely used in wellness clinics and anti-aging practices as an unregulated nutraceutical/supplement administered off-label. It is not explicitly listed on the FDA’s Section 503A Category 2 list, but compounded injectable NAD+ preparations remain subject to general compounding pharmacy regulations and require sterility and purity assurance. The FDA has not specifically targeted injectable NAD+ in its 2023–2024 peptide compounding enforcement actions
• MOTS-c: Not FDA-approved for any indication. Not currently on the FDA’s 503A Category 2 list. No IND has been filed for MOTS-c in humans as of early 2026. Research active at USC and other institutions; human trials are anticipated but have not been initiated
• 5-Amino-1MQ: Not FDA-approved. Not a peptide — it is a small molecule. Not currently on the FDA’s 503A/503B compounding substance lists. There is no regulatory framework specific to 5-Amino-1MQ’s use in humans; it is sold as a research chemical. Its status as a small molecule (rather than a peptide) means it falls outside the peptide-specific regulatory actions taken in 2023–2024, but it remains an unapproved new drug if sold for human therapeutic use

WADA Status

• NAD+: Not on the WADA 2025 or 2026 Prohibited Lists. NAD+ is an endogenous human coenzyme; supplementation does not constitute doping under current WADA definitions​
• MOTS-c: Not explicitly listed on the WADA 2025 or 2026 Prohibited Lists. MOTS-c does not fall under any named category in the S0–S9 framework. As a peptide encoded by mitochondrial DNA that acts primarily via AMPK/metabolic pathways (rather than anabolic hormone stimulation), it does not clearly fit existing prohibited categories. This may change as the compound advances toward clinical use
• 5-Amino-1MQ: Not on the WADA Prohibited Lists​

The metabolic blend occupies the most favorable regulatory position of all combinations in this catalog from a WADA perspective — none of the three components is currently explicitly prohibited.

NAD+ Safety

• Oral precursors (NR, NMN): Extensively characterized as safe in multiple human RCTs; no significant adverse events at doses up to 2,000 mg/day of NR or 500 mg/day of NMN in published trials
• Injectable NAD+ (IM/SC): Clinic experience at doses of 100–500 mg reports most adverse effects are infusion rate-dependent — rapid IV administration causes nausea, flushing, chest tightness, and headache; slower administration rates and IM/SC routes are generally better tolerated
• Contraindications: Theoretical concern exists that NAD+ supplementation could accelerate growth of pre-existing malignancies through enhanced DNA repair capacity in tumor cells (via PARP1) — an unresolved question not addressed by any clinical safety study​
• Well-established safety at physiological doses: NAD+ is a naturally occurring essential coenzyme; supplement-level doses have a strong safety record

MOTS-c Safety

• No published human safety data exists for exogenous synthetic MOTS-c by any route​
• In all preclinical studies (IP injection at 5–15 mg/kg/day in mice over weeks to months), MOTS-c was uniformly well tolerated with no reported organ toxicity, behavioral abnormalities, or adverse events
• The peptide’s natural origin (mitochondrial DNA, expressed in human tissues) and age-dependent decline (not excess) suggest an intrinsically favorable safety architecture
• No mutagenicity, teratogenicity, or carcinogenicity data has been published for MOTS-c
• No WADA anti-doping detection methods have been developed or published for MOTS-c

5-Amino-1MQ Safety

• No human safety data of any kind has been published
• Preclinical mouse studies showed weight loss and metabolic improvements with no reported organ toxicity or adverse effects, but formal toxicology (GLP-compliant multi-dose organ toxicity studies) has not been published
• Subcutaneous injection specifically has not been evaluated in any published study — pharmacokinetic data exists only for IV and oral routes in rats​
• 5-Amino-1MQ’s status as a methylquinolinium small molecule (an N-methylated aromatic amine) introduces theoretical questions about genotoxicity that would require formal Ames test, in vitro chromosomal aberration, and in vivo micronucleus studies before human use could be responsibly characterized — none of these have been published
• The orally bioavailable, small molecule character of 5-Amino-1MQ means that it distributes more broadly and potentially has different tissue distribution than injectable peptides — an important consideration for safety assessment

Blend-Level Synergy and Safety Considerations

• No pharmacological antagonism is expected between the three components — they operate through distinct, non-competing pathways​
• The convergence on the NAD+/SIRT1/AMPK/PGC-1α axis through three independent inputs creates pharmacological reinforcement rather than redundancy or competition
• Injection site reactions for NAD+ (IM/SC) and MOTS-c (SC) are expected; 5-Amino-1MQ is typically administered orally
• The research-to-clinical gap is largest for this blend compared to others in this catalog: while NAD+ precursor safety is well established in oral form, and MOTS-c and 5-Amino-1MQ have favorable preclinical profiles, the combination of all three via injectable routes in humans has no published safety data and significant unknowns

NAD+

1. Cantó, C., et al. (2015). NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metabolism, 22(1), 31–53.
2. Verdin, E. (2014). NAD+ and Sirtuins in Aging and Disease. Trends in Cell Biology, 24(8), 464–471. 
3. Covarrubias, A.J., et al. (2019). Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases. Antioxidants & Redox Signaling, 34(4), 299–344. 
4. Martens, C.R., et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. 
5. Brakedal, B., et al. (2020). Clinical Evidence for Targeting NAD Therapeutically. Pharmaceuticals, 13(9), 247. 
6. He, Q., et al. (2023). NAD+ Precursors NMN and NR: A Review. Antioxidants, 12(6), 1224. 
7. Belenky, P., et al. (2019). Nicotinamide Mononucleotide: A Promising Molecule for Diverse Diseases. Frontiers in Cell and Developmental Biology, 8. 
8. NuRev Peptides. (2026). NAD Injection: A Complete Guide to Benefits, Safety, and Clinical Use. 

MOTS-c
9. Lee, C., et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 21(3), 443–454. 
10. Lee, C., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12, 470. 
11. Reynolds, J.C., et al. (2021). MOTS-c interacts synergistically with exercise to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism via AMPK. Biochemical Pharmacology, 187, 114405. 
12. Bhatt, M., et al. (2023). MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 21, 36. 
13. Lu, H., et al. (2019). MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 7(10), e14171. 
14. Li, H., et al. (2022). MOTS-c, the Most Recent Mitochondrial-Derived Peptide in Human Aging. Aging and Disease, 13(3), 801–814. 
15. USC Today. (2023). The molecule that might fight off frailty and foster fitness as we age. 

5-Amino-1MQ
16. Neelakantan, H., et al. (2017). Selective and membrane-permeable small molecule inhibitors of NNMT reverse obesity-induced adipocyte mitochondrial dysfunction. Biochemical Pharmacology, 147, 67–75. 
17. Neelakantan, H., et al. (2018). 5-amino-1MQ reduces body weight and fat mass in diet-induced obese mice. Biochemical Pharmacology, 151, 91–101.
18. PeptideFox. (2026). 5-Amino-1MQ: The NNMT Inhibitor That Reprograms Fat Cell Metabolism. 
19. Swolverine. (2025). How 5-Amino-1MQ Works: Mechanism, Benefits, Stacking, and Cycling Guide. 
20. DrOracle AI. (2025). What Are the Safety and Efficacy of Subcutaneous Dosing of 5-Amino-1MQ?